Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
Insmed (NASDAQ:INSM) reported top-line results from its phase III ENCORE trial evaluating ARIKAYCE in adults with non-cavitary lung disease and a newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung infection who had not yet begun antibiotics for their current infection. Company executives described the trial as a “clear success,” citing statistically significant benefits on patient-reported respiratory symptoms and multiple culture conversion endpoints, along with a safety profile consistent with prior experience. Trial design and endpoints Chief Medical Officer Martina Flammer said ENCORE enrolled 425 adult patients. Participants were randomized 1:1 to receive either: ARIKAYCE plus azithromycin and ethambutol, or an empty liposome placebo plus azithromycin and ethambutol. ? The S&P 500 Broke Its 200-Day Moving Average—Here's What to Expect Stock Rotation is Underway: Here are the Winners Moving Forward Treatment was administered once daily for 12 months
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]Yahoo! Finance
- Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.MarketBeat
- S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]Barrons
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 3/23/26 - Form 8-K
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- INSM's page on the SEC website